Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial.
Fiche publication
Date publication
avril 2023
Journal
BMJ open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric
Tous les auteurs :
Desmarets M, Hoffmann S, Vauchy C, Rijnders BJA, Toussirot E, Durrbach A, Körper S, Schrezenmeier E, van der Schoot CE, Harvala H, Brunotte G, Appl T, Seifried E, Tiberghien P, Bradshaw D, Roberts DJ, Estcourt LJ, Schrezenmeier H
Lien Pubmed
Résumé
COVID-19 convalescent plasma (CCP) is a possible treatment option for COVID-19. A comprehensive number of clinical trials on CCP efficacy have already been conducted. However, many aspects of CCP treatment still require investigations: in particular (1) Optimisation of the CCP product, (2) Identification of the patient population in need and most likely to benefit from this treatment approach, (3) Timing of administration and (4) CCP efficacy across viral variants in vivo. We aimed to test whether high-titre CCP, administered early, is efficacious in preventing hospitalisation or death in high-risk patients.
Mots clés
Blood bank & transfusion medicine, COVID-19, Clinical trials, INFECTIOUS DISEASES, Respiratory infections
Référence
BMJ Open. 2023 04 27;13(4):e071277